mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

被引:135
|
作者
Watanabe, Ryosuke [1 ]
Wei, Liu
Huang, Jing
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
基金
美国国家卫生研究院;
关键词
mTOR structure; mTOR therapy; mTORC; MAMMALIAN TARGET; RAPAMYCIN; EVEROLIMUS; COMPLEX; PROTEIN; KINASE; RICTOR; AKT; SUPPRESSION; METABOLISM;
D O I
10.2967/jnumed.111.089623
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Mammalian target of rapamycin (mTOR) is an evolutionally conserved serine/threonine kinase that integrates signals from multiple pathways, including nutrients (e. g., amino acids and glucose), growth factors (e. g., insulin and insulinlike growth factor 1), hormones (e. g., leptin), and stresses (e. g., starvation, hypoxia, and DNA damage) to regulate a wide variety of eukaryotic cellular functions, such as translation, transcription, protein turnover, cell growth, differentiation, cell survival, metabolism, energy balance, and stress response. Dysregulation of the mTOR pathway is closely associated with cancers and other human diseases. Thus, mTOR is of considerable interest in view of its potential as a therapeutic drug target. However, only limited success has been achieved in clinical applications of mTOR inhibitors because of the inherent complexity in the regulation and function of mTOR. Emerging new developments in this area, such as novel readouts (potential biomarkers) for mTOR activity, dynamic assembly and translocation of the mTOR complex, cross-regulation between mTOR complex 1 and mTOR complex 2 via inter-and intracomplex loops, new mTOR regulators, and new inhibitors, are providing insights that may help overcome these challenges. The introduction of innovative imaging strategies is also expected to give rise to breakthroughs in understanding mTOR network complexity and mTOR inhibitor action by visualizing the regulation and function of mTOR.
引用
收藏
页码:497 / 500
页数:4
相关论文
共 50 条
  • [21] Gamma Secretase Inhibitors as Potential Therapeutic Targets for Notch Signaling in Uterine Leiomyosarcoma
    Abedin, Yasmin
    Gabrilovich, Sofia
    Alpert, Emily
    Rego, Erica
    Begum, Salma
    Zhao, Qingshi
    Heller, Debra
    Einstein, Mark H.
    Douglas, Nataki C.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (11)
  • [22] Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies
    Mehta, Devashish
    Rajput, Kajal
    Jain, Dolly
    Bajaj, Avinash
    Dasgupta, Ujjaini
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2024, 7 (12) : 3758 - 3779
  • [23] Therapeutic Targets for Inhibitors of Glycosylation
    Alonzi, Dominic S.
    Butters, Terry D.
    CHIMIA, 2011, 65 (1-2) : 35 - 39
  • [24] mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
    Zou, Zhilin
    Tao, Tao
    Li, Hongmei
    Zhu, Xiao
    CELL AND BIOSCIENCE, 2020, 10 (01):
  • [25] mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
    Zhilin Zou
    Tao Tao
    Hongmei Li
    Xiao Zhu
    Cell & Bioscience, 10
  • [26] The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches
    Ihlamur, Murat
    Akgul, Busra
    Zengin, Yagmur
    Korkut, Senay Vural
    Kelleci, Kubra
    Abamor, Emrah Sefik
    CURRENT MOLECULAR MEDICINE, 2024, 24 (04) : 478 - 494
  • [27] Osteosarcoma and chondrosarcoma: New signaling pathways as targets for novel therapeutic interventions
    Papachristou, Dionysios J.
    Papavassiliou, Athanasios G.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2007, 39 (05): : 857 - 862
  • [28] Histone deacetylases function as novel potential therapeutic targets for cancer
    Zhang, Hui
    Shang, Yu-Ping
    Chen, Hong-ying
    Li, Jun
    HEPATOLOGY RESEARCH, 2017, 47 (02) : 149 - 159
  • [29] Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives
    Soltani, Arash
    Bahreyni, Amirhossein
    Boroumand, Nadia
    Roshan, Mostafa Karimi
    Khazaei, Majid
    Ryzhikov, Mikhail
    Soleimanpour, Saman
    Avan, Amir
    Hassanian, Seyed Mahdi
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (06) : 4783 - 4790
  • [30] Novel therapeutic targets
    Geppetti, P.
    Trevisani, M.
    Nicoletti, P.
    Capone, J. G.
    NEUROLOGICAL SCIENCES, 2006, 27 (Suppl 2) : S111 - S114